Repligen initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Doug Schenkel initiated coverage of Repligen (RGEN) with a Peer Perform rating and no price target Bioprocessing tools is currently a $20B market that should return to high-single-digit or low-double-digit growth through 2030, the analyst tells investors in a research note. The firm says Repligen is a unique bioprocessing asset with particular strength in chromatography and filtration. It believes Repligen is positioned well for consistent above-market growth and margin expansion, but says the stock’s valuation leaves little room for upside from current levels.